Identification and molecular analysis of 17 novel variants of hydroxymethylbilane synthase in Chinese patients with acute intermittent porphyria

• Published in: Clinical genetics 2022-01, Vol.101 (1), p.116-121
• Main Authors: Hu, Yuanxiang, Li, Weihao, Kang, Ninglin, Ma, Liyan, Teng, Qing, Mo, Guiling, Wu, Jiahong, Wang, Xinyang, Bi, Renjie, Zhang, Songyun
• Format: Article
• Language: English
• Subjects: acute intermittent porphyria; Alleles; Cell Line; China; expression level; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Heme; Hereditary diseases; Humans; hydroxymethylbilance synthase; Hydroxymethylbilane synthase; Hydroxymethylbilane Synthase - genetics; Immunofluorescence; Insertion; molecular diagnosis; Mutants; Mutation; Pathogenicity; Patients; Phenotype; Porphyria; Porphyria, Acute Intermittent - diagnosis; Porphyria, Acute Intermittent - genetics; variants; Western blotting
• ISSN: 0009-9163; 1399-0004
• DOI: 10.1111/cge.14063

A partial deficiency of the heme biosynthetic enzyme hydroxymethylbilane synthase (HMBS) leads to acute intermittent porphyria (AIP), a severe neurovisceral, autosomal dominant disorder with low penetrance. Even though in‐depth investigations of the HMBS variants have been carried out by researchers in Britain, France, Russia, and Sweden, this area remains uninvestigated in China owing to the rarity and lack of clinical understanding of the disease. In this study, 78 unrelated AIP patients revealed 48 different HMBS variants, of which 17 were novel. These included 22 missense variants, 9 splicings, 5 nonsense variants, 10 small deletions, 1 repeat insertion, and 1 complex deletion–insertion variant. The variant c.673C > T, found in 10 unrelated patients, was the most frequent variant, followed by the variant c.517C > T, found in 7 unrelated patients. We performed western blotting and immunofluorescence staining with four novel variants (c.653G > A, c.597dupC, c.726‐727del, and c.1045_1046delAA) to detect the expression levels of mutant HMBSs. The results showed a variant‐mediated decrease in the mutant‐HMBS level, suggesting that the variant resulted in impaired gene product functions. Moreover, the in vitro functional verification in this study provided PS3_moderate evidence for American College of Medical Genetics and Genomics (ACMG) to grade the pathogenicity of novel variants in AIP.